NASDAQ:CKPT - Checkpoint Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.67
  • Forecasted Upside: 450.36 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.21
▼ -0.06 (-1.83%)
1 month | 3 months | 12 months
Get New Checkpoint Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CKPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CKPT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.67
▲ +450.36% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Checkpoint Therapeutics in the last 3 months. The average price target is $17.67, with a high forecast of $20.00 and a low forecast of $16.00. The average price target represents a 450.36% upside from the last price of $3.21.
Buy
The current consensus among 3 investment analysts is to buy stock in Checkpoint Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2021Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by J. Kim at Cantor Fitzgerald
1/19/2021Cantor FitzgeraldInitiated CoverageOverweight$16.00High
i
Rating by L. Chen at Cantor Fitzgerald
9/29/2020HC WainwrightBoost Price TargetBuy$15.00 ➝ $17.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/6/2020HC WainwrightReiterated RatingBuy$15.00High
i
Rating by Joseph Pantginis at HC Wainwright
7/15/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00Medium
i
6/25/2020HC WainwrightReiterated RatingBuy$15.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/12/2020HC WainwrightReiterated RatingBuy$15.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/27/2019Lake Street CapitalReiterated RatingBuy$12.00 ➝ $8.00High
i
9/30/2019HC WainwrightReiterated RatingBuy$15.00Low
i
8/9/2019HC WainwrightReiterated RatingBuy$15.00Medium
i
5/29/2019Lake Street CapitalInitiated CoverageBuy ➝ BuyMedium
i
5/1/2019HC WainwrightBoost Price TargetBuy$11.00 ➝ $15.00High
i
Rating by Joseph Pantginis at HC Wainwright
1/14/2019HC WainwrightSet Price TargetBuy$11.00High
i
Rating by Joseph Pantginis at HC Wainwright
11/2/2018HC WainwrightSet Price TargetBuy$11.00Low
i
Rating by Joseph Pantginis at HC Wainwright
9/6/2018HC WainwrightSet Price TargetBuy$11.00Low
i
Rating by Joseph Pantginis at HC Wainwright
8/20/2018HC WainwrightSet Price TargetBuy$11.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
8/8/2018HC WainwrightReiterated RatingBuy$11.00High
i
5/11/2018HC WainwrightReiterated RatingBuy$11.00High
i
Rating by J. Pantginis at HC Wainwright
12/8/2017HC WainwrightInitiated CoverageBuy ➝ Buy$11.00High
i
Rating by J. Pantginis at HC Wainwright
3/22/2017LADENBURG THALM/SH SHInitiated CoverageBuyLow
i
(Data available from 2/28/2016 forward)
Checkpoint Therapeutics logo
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Read More

Today's Range

Now: $3.21
$3.07
$3.34

50 Day Range

MA: $3.48
$2.71
$4.16

52 Week Range

Now: $3.21
$1.05
$5.38

Volume

1,447,079 shs

Average Volume

1,647,595 shs

Market Capitalization

$217.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Checkpoint Therapeutics?

The following sell-side analysts have issued reports on Checkpoint Therapeutics in the last year: Cantor Fitzgerald, HC Wainwright, and LADENBURG THALM/SH SH.
View the latest analyst ratings for CKPT.

What is the current price target for Checkpoint Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Checkpoint Therapeutics in the last year. Their average twelve-month price target is $17.67, suggesting a possible upside of 450.4%. LADENBURG THALM/SH SH has the highest price target set, predicting CKPT will reach $20.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $16.00 for Checkpoint Therapeutics in the next year.
View the latest price targets for CKPT.

What is the current consensus analyst rating for Checkpoint Therapeutics?

Checkpoint Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CKPT will outperform the market and that investors should add to their positions of Checkpoint Therapeutics.
View the latest ratings for CKPT.

What other companies compete with Checkpoint Therapeutics?

How do I contact Checkpoint Therapeutics' investor relations team?

Checkpoint Therapeutics' physical mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company's listed phone number is 781-652-4500 and its investor relations email address is [email protected] The official website for Checkpoint Therapeutics is www.checkpointtx.com.